BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

被引：0
作者：
Marcel Ebeling
Mario Scheurer
Andreas Sakkas
Sebastian Pietzka
Alexander Schramm
Frank Wilde
机构：
[1] Academic Hospital of the University of Ulm,Department of Oral and Plastic Maxillofacial Surgery, Military Hospital Ulm
[2] University Hospital Ulm,Department of Oral and Plastic Maxillofacial Surgery
来源：
Medical Oncology | / 40卷
关键词：
Ameloblastoma; BRAF; Facial reconstruction; Chemotherapy; Dabrafenib; Vemurafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy
    Tijtgat, Jens
    Schwarze, Julia Katharina
    Awada, Gil
    Neyns, Bart
    Aspeslagh, Sandrine
    MELANOMA RESEARCH, 2021, 31 (03) : 272 - 276
  • [32] Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma
    Tseng, Chih-Huang
    Lu, Pei-Hsuan
    Wang, Yi-Ping
    Chang, Julia Yu Fong
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (01):
  • [33] Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
    Fasano, Morena
    Della Corte, Carminia Maria
    Caterino, Marianna
    Pirozzi, Mario
    Rauso, Raffaele
    Troiani, Teresa
    Martini, Giulia
    Napolitano, Stefania
    Morgillo, Floriana
    Ciardiello, Fortunato
    FRONTIERS IN MEDICINE, 2022, 8
  • [34] Selection Strategies and Practical Application of BRAF V600E-Mutated Non-Small Cell Lung Carcinoma
    Hwang, Inwoo
    Choi, Yoon-La
    Lee, Hyunwoo
    Hwang, Soohyun
    Lee, Boram
    Yang, Hobin
    Chelakkot, Chaithanya
    Han, Joungho
    CANCER RESEARCH AND TREATMENT, 2022, 54 (03): : 782 - 792
  • [35] BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma
    Walter, Lisa
    Heinzerling, Lucie
    ANTICANCER RESEARCH, 2018, 38 (03) : 1335 - 1341
  • [36] Cell-SELEX-based selection of ssDNA aptamers for specifically targeting BRAF V600E-mutated melanoma
    Li, Wanming
    Bing, Tao
    Wang, Rui
    Jin, Sihan
    Shangguan, Dihua
    Chen, Hang
    ANALYST, 2021, 147 (01) : 187 - 195
  • [37] E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases
    Babiker, Hani M.
    Byron, Sara A.
    Hendricks, William P. D.
    Elmquist, William F.
    Gampa, Gautham
    Vondrak, Jessica
    Aldrich, Jessica
    Cuyugan, Lori
    Adkins, Jonathan
    De Luca, Valerie
    Tibes, Raoul
    Borad, Mitesh J.
    Marceau, Katie
    Myers, Thomas J.
    Paradiso, Linda J.
    Liang, Winnie S.
    Korn, Ronald L.
    Cridebring, Derek
    Von Hoff, Daniel D.
    Carpten, John D.
    Craig, David W.
    Trent, Jeffrey M.
    Gordon, Michael S.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 636 - 645
  • [38] The histopathology of BRAF-V600E-mutated lung adenocarcinoma
    Yousem, Samuel A.
    Nikiforova, Marina
    Nikiforov, Yuri
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2008, 32 (09) : 1317 - 1321
  • [39] Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance
    Ernst, Tina
    Aebi, Stefan
    Zander, Andrea
    Zander, Thilo
    BMJ CASE REPORTS, 2022, 15 (04)
  • [40] Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib
    Marks, Asher M.
    Bindra, Ranjit S.
    DiLuna, Michael L.
    Huttner, Anita
    Jairam, Vikram
    Kahle, Kristopher T.
    Kieran, Mark W.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (05)
12345